Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC
Recruiting
Phase 1
Interventional Study
Head and Neck Cancer
Relapse
Recurrent
Refractory Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 33 (estimated)
- Sponsor
- UNC Lineberger Comprehensive Cancer Center · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the CSPG4 antigen (iC9.CAR-CSPG4 T cells) in patients with head and neck cancer that came back after receiving standard therapy for this cancer. The iC9.CAR-CSPG4 treatment is experimental and has not been approved by the Food and Drug Adm…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Unless otherwise noted, subjects must meet all of the following criteria to participate in all phases of the study:
1. Written informed consent and HIPAA authorization for release of personal health information explained to, understood by and signed by the subject; subject give…
Contacts